Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor-Reference-Cited by-同舟云学术

Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor

Published:2014-08-13 Issue:4 Volume:56 Page:1012-1019
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Chen Yiming,Estrov Zeev,Pierce Sherry,Qiao Wei,Borthakur Gautam,Ravandi Farhad,Kadia Tapan,Brandt Mark,O’Brien Susan,Jabbour Elias,Garcia-Manero Guillermo,Cortes Jorge,Beran Miloslav

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.946023

Reference31 articles.

1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

2. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML

3. Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin’s Disease: A Report From the German Hodgkin’s Lymphoma Study Group

4. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

5. Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION.;Mediterranean Journal of Hematology and Infectious Diseases;2023-08-29

2. Clinical outcome of therapy‐related acute myeloid leukemia patients. Real‐life experience in a University Hospital and a Cancer Center in France;Cancer Medicine;2023-08

3. Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group;JCO Precision Oncology;2023-01

4. Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer;Haematologica;2022-06-30